IL-17 May Play Role Linking Pathogenesis of Psoriasis to Metabolic Disease
Interleukin (IL)-17 is a group of cytokines secreted by neutrophils, mast cells, and cytotoxic T cells and plays a major role in immunity against bacteria and fungi. The IL-17 group also has a role in the development of inflammatory and autoimmune diseases. Psoriasis is an inflammatory autoimmune disease where IL-17 plays a specific role. We now know that psoriasis has numerous concomitant metabolic disorders associated with the disease. Studies have demonstrated that concentrations of IL-17A as well as IL-17C and IL-17F are higher in psoriatic lesions than in healthy skin and treatment of psoriasis with anti-IL-17 monoclonal antibodies shows promising results in clearing psoriatic plaques.
A recent study reviewed the research clarifying the role of IL-17A in lipid metabolism, cardiovascular diseases, atherosclerosis, insulin resistance and diabetes, and obesity. The article lays out the research evidence explaining the mechanism of IL-17 and how it relates to psoriasis and other metabolic diseases. For example, increased IL-17A production may explain an increased risk of myocardial infarction in patients with psoriasis. The authors suggest that while the exact role of IL-17A remains controversial, evidence suggests that it may be considered an important factor that explains their more rapid development in patients with psoriasis. Further understanding the role of IL-17 and the use of anti IL-17 treatments may hold promise for inhibiting the development of metabolic disorders in patients with psoriasis.
Byline: Martha L. Sikes, MS, RPh, PA-C
Posted: March 20, 2017
Adapted from the original article.